COVID-2019 Alert

The latest information about the 2019 Novel Coronavirus, including vaccine clinics for children ages 6 months and older.

La información más reciente sobre el nuevo Coronavirus de 2019, incluidas las clínicas de vacunación para niños de 6 meses en adelante.


Transfer of Abnormal and Mosaic Embryos Study (TAME)

This clinical research study will investigate the pregnancy outcomes of transferring abnormal and mosaic embryos. Mosaic embryos have both chromosomally normal and chromosomally abnormal cells. Sometimes, these mosaic or abnormal embryos are the only option available for in vitro fertilization treatments. This is the first study that will look at the pregnancy outcomes after transfer of chromosomally abnormal embryos in humans.

Who is eligible to participate?

You are eligible to participate if you meet the following criteria:

  • You desire transfer of abnormal and mosaic embryos after your PGT-A (preimplantation genetic testing for aneuploidy, or the presence of an abnormal number of chromosomes in a cell).
  • You agree to undergo counseling with our genetic counselor and pass a mandatory 30-day waiting period.

What does the study participation involve?

  • Following your and our other study participants’ pregnancies outcomes after transfer of abnormal or mosaic embryos (three months, two years, five years).
  • Undergoing invasive prenatal testing (amniocentesis) during pregnancy—it is recommended but not required.
  • Donating placenta and cord blood at delivery for banking.

For more information, please contact us:

Email Stanford Medicine Fertility and Reproductive Health research team.

Fertility and Reproductive Health logo